Publications by authors named "Tuuli Ranki"

Claim this Profile
R
Real-world evidence of multiple myeloma treated from 2013 to 2019 in the Hospital District of Helsinki and Uusimaa, Finland.
Johanna Vikkula, Kristiina Uusi-Rauva, Tuuli Ranki, Iiro Toppila, Maria Aalto-Setälä

Future Oncol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Retrospective, Registry-based, Cohort Investigation of Clinical Outcomes in Patients with Cutaneous Squamous Cell Carcinoma and Basal Cell Carcinoma in Finland.
Samuli Tuominen, Liisa Ukkola-Vuoti, Pilvi Riihilä, Jaakko S Knuutila, Veli-Matti Kähäri, Tuuli Ranki

Acta Derm Venereol· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of a novel OX40 ligand and CD40 ligand-expressing oncolytic adenovirus used in the PeptiCRAd cancer vaccine platform.
Erkko Ylösmäki, Leena Ylösmäki, Manlio Fusciello, Beatriz Martins, Petra Ahokas, Tuuli Ranki

Mol Ther Oncolytics· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploiting Preexisting Immunity to Enhance Oncolytic Cancer Immunotherapy.
Siri Tähtinen, Sara Feola, Cristian Capasso, Netta Laustio, Christianne Groeneveldt, Tuuli Ranki

Cancer Res· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Toxicological and bio-distribution profile of a GM-CSF-expressing, double-targeted, chimeric oncolytic adenovirus ONCOS-102 - Support for clinical studies on advanced cancer treatment.
Lukasz Kuryk, Lotta Vassilev, Tuuli Ranki, Akseli Hemminki, Aila Karioja-Kallio

PLoS One· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synergistic anti-tumor efficacy of immunogenic adenovirus ONCOS-102 (Ad5/3-D24-GM-CSF) and standard of care chemotherapy in preclinical mesothelioma model.
Lukasz Kuryk, Elina Haavisto, Mariangela Garofalo, Cristian Capasso, Mari Hirvinen, Tuuli Ranki

Int J Cancer· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study with ONCOS-102 for the treatment of solid tumors - an evaluation of clinical response and exploratory analyses of immune markers.
Tuuli Ranki, Sari Pesonen, Akseli Hemminki, Kaarina Partanen, Kalevi Kairemo

J Immunother Cancer· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Local treatment of a pleural mesothelioma tumor with ONCOS-102 induces a systemic antitumor CD8 T-cell response, prominent infiltration of CD8 lymphocytes and Th1 type polarization.
Tuuli Ranki, Timo Joensuu, Elke Jäger, Julia Karbach, Claudia Wahle

Oncoimmunology· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oncolytic immunotherapy of advanced solid tumors with a CD40L-expressing replicating adenovirus: assessment of safety and immunologic responses in patients.
Sari Pesonen, Iulia Diaconu, Lotta Kangasniemi, Tuuli Ranki, Anna Kanerva

Cancer Res· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF.
Anniina Koski, Lotta Kangasniemi, Sophie Escutenaire, Sari Pesonen, Vincenzo Cerullo, Tuuli Ranki

Mol Ther· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serotype chimeric human adenoviruses for cancer gene therapy.
Tuuli Ranki, Akseli Hemminki

Viruses· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tissue-specific promoters active in CD44+CD24-/low breast cancer cells.
Gerd J Bauerschmitz, Tuuli Ranki, Lotta Kangasniemi, Camilla Ribacka, Minna Eriksson

Cancer Res· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of metastatic renal cancer with capsid-modified oncolytic adenoviruses.
Kilian Guse, Tuuli Ranki, Martti Ala-Opas, Petri Bono, Merja Särkioja

Mol Cancer Ther· October 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systemic efficacy of oncolytic adenoviruses in imagable orthotopic models of hormone refractory metastatic breast cancer.
Tuuli Ranki, Merja Särkioja, Tanja Hakkarainen, Karl von Smitten, Anna Kanerva

Int J Cancer· July 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chlorpromazine and apigenin reduce adenovirus replication and decrease replication associated toxicity.
Anna Kanerva, Mari Raki, Tuuli Ranki, Merja Särkioja, Jarmo Koponen

J Gene Med· January 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Noninvasive imaging for evaluation of the systemic delivery of capsid-modified adenoviruses in an orthotopic model of advanced lung cancer.
Merja Sarkioja, Anna Kanerva, Jarmo Salo, Lotta Kangasniemi, Minna Eriksson, Tuuli Ranki

Cancer· October 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Infectivity-enhanced adenoviruses deliver efficacy in clinical samples and orthotopic models of disseminated gastric cancer.
Lotta Kangasniemi, Tuula Kiviluoto, Anna Kanerva, Mari Raki, Tuuli Ranki

Clin Cancer Res· May 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis